Adoption and implementation of medications in addiction treatment programs

Journal of Addiction Medicine

Volumn 5, Issue 1, 2011, Pages 21-27

  Knudsen, Hannah K ^a   Abraham, Amanda J ^a   Roman, Paul M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Addiction treatment programs; Implementation research; Medications

Indexed keywords

ACAMPROSATE; ALCOHOL; BUPRENORPHINE; DISULFIRAM; METHADONE; NALTREXONE; NEUROLEPTIC AGENT; OPIATE;

ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HUMAN; INTERVIEW; MENTAL DISEASE; OPIATE ADDICTION; PHYSICIAN; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; TREATMENT PLANNING; UNITED STATES;

ALCOHOL DETERRENTS; ALCOHOLISM; COMORBIDITY; DRUG UTILIZATION; HEALTH PLAN IMPLEMENTATION; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES RESEARCH; HUMANS; MENTAL DISORDERS; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; PSYCHOTROPIC DRUGS; SUBSTANCE ABUSE TREATMENT CENTERS; UNITED STATES;

EID: 79954492456     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3181d41ddb     Document Type: Article

References (32)

1. Abraham AJ, Ducharme LJ, Roman PM. Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs 2009;70: 628-635.
2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (Treatment Improvement Protocol Series 40, DHHS Publication SMA 04-3939). Rockville, MD: SAMHSA, 2004.
3. Ducharme LD, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy 2008;3:17.
4. Ducharme LJ, Knudsen HK, Roman PM. Trends in the adoption of medications for alcohol dependence. J Clin Psychopharmacol 2006; 26(suppl 1):S13-S19. (Pubitemid 44772725)
5. Ducharme LJ, Knudsen HK, Roman PM, et al. Innovation adoption in substance abuse treatment: Exposure, trialability, and the clinical trials network. J Subst Abuse Treat 2007;32:321-329. (Pubitemid 46661128)
6. Fitzgerald J, McCarty D. Understanding attitudes toward use of medications in substance abuse treatment: A multilevel approach. Psychol Serv 2009;6:74-84.
7. Friedmann PD, Jiang L, Alexander JA. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. J Behav Health Serv Res 2010;373:322-337.
8. Fuller BE, Rieckmann T, McCarty D, et al. Adoption of naltrexone to treat alcohol dependence. J Subst Abuse Treat 2005;28:273-280. (Pubitemid 40592129)
9. Heinrich CJ, Hill CJ. Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res 2008;43:951-970. (Pubitemid 351623961)
10. Horgan CM, Reif S, Hodgkin D, et al. Availability of medications in private health plans. J Subst Abuse Treat 2008;34:147-156. (Pubitemid 351163511)
11. Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis 2006;25:91-103. (Pubitemid 44707293)
12. Knudsen HK, Abraham AJ, Johnson JA, et al. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat 2009;37:307-312.
13. Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. J Subst Abuse Treat 2006;30:363-373. (Pubitemid 43729149)
14. Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend 2007a;87:164-174. (Pubitemid 46215923)
15. Knudsen HK, Ducharme LJ, Roman PM. The use of antidepressant medications in substance abuse treatment: The public-private distinction, organizational compatibility, and the environment. J Health Soc Behav 2007b;48:195-210.
16. Knudsen HK, Ducharme LJ, Roman PM. Racial and ethnic disparities in SSRI availability in substance abuse treatment. Psychiatr Serv 2007c; 58:55-62.
17. Knudsen HK, Ducharme LJ, Roman PM, et al. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. J Subst Abuse Treat 2005a;29:95-106. (Pubitemid 41749339)
18. Knudsen HK, Roman PM. Modeling the use of innovations in private treatment organizations: The role of absorptive capacity. J Subst Abuse Treat 2004;26:353-361. (Pubitemid 38041230)
19. Knudsen HK, Roman PM, Ducharme LD, et al. Organizational predictors of pharmacological innovation adoption: The case of disulfiram. J Drug Issues 2005b;35:559-574. (Pubitemid 41393189)
20. Koch AL, Arfken C, Schuster CR. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend 2005;83:274-278.
21. Mark TL, Kranzler HR, Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 2003;71: 219-228. (Pubitemid 38368573)
22. Mark TL, Swait J. Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications. Value Health 2003;6:474-484.
23. Mark TL, Swait J. Using stated preference and revealed preference modeling to evaluated prescribing decisions. Health Econ 2004;13:563-573. (Pubitemid 38787148)
24. Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat 2009;36:244-251.
25. Reif S, Thomas CP, Wallack SS. Factors determining how early adopter physicians use buprenorphine in treatment. J Addict Med 2007;1:205-212.
26. Rieckmann T, Daley M, Fuller BE, et al. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat 2007;32:207-215. (Pubitemid 46240725)
27. Roman PM, Johnson JA. Adoption and implementation of new technologies in substance abuse treatment. J Subst Abuse Treat 2002;22: 211-218. (Pubitemid 34606039)
28. Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey of Substance Abuse Treatment Services: 2007. Rockville, MD: Office of Applied Studies, SAMHSA; 2008.
29. Thomas CP, Reif S, Haq S, et al. Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatr Serv 2008;59:909-916.
30. Thomas CP, Wallack SS, Lee S, et al. Research to practice: Adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat 2003;24:1-11. (Pubitemid 36315767)
31. Vocci F, Ling W. Medications development: Successes and challenges. Pharmacol Ther 2005;108:94-108. (Pubitemid 41377122)
32. Wallack SS, Thomas CP, Martin TC, et al. Substance abuse treatment organizations as mediators of social policy: Slowing the adoption of a congressionally approved medication. J Behav Health Serv Res 2010; 37:64-78.